Because the systemic bioavailability is <1% (using a sensitive assay with a lower quantitation limit of 0.25 pg/ml) after administration of mometasone furoate via MFNS, overdose is unlikely to require any therapy other than observation.
Inhalation or oral administration of excessive doses of corticosteroids may lead to suppression of hypopituitary-adrenal (HPA) axis function.